[{"address1": "41 \u2013 47 Colin Street", "address2": "Suite 3", "city": "West Perth", "state": "WA", "zip": "6005", "country": "Australia", "phone": "61 8 6555 2945", "fax": "61 8 6210 1153", "website": "https://www.botanixpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia and the United States. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIa clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. Botanix Pharmaceuticals Limited was incorporated in 1984 and is based in West Perth, Australia.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Vincent P. Ippolito", "age": 64, "title": "MD & Executive Chairman", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 461919, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Howie  McKibbon", "title": "Chief Executive Officer", "fiscalYear": 2024, "totalPay": 696368, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Graeme  Morissey", "title": "Chief Financial Officer", "fiscalYear": 2024, "totalPay": 69243, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Callahan L.L.B., M.B.A., MBA LLB", "age": 50, "title": "Executive Director", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 269259, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jack  Hoblitzell Ph.D.", "title": "Senior Vice President of Pharmaceutical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Patricia S. Walker M.D., Ph.D.", "age": 64, "title": "Chief Medical Adviser", "yearBorn": 1959, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Boris  Meyerson Ph.D.", "title": "Chief Business Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David  Morgan", "title": "Head of Corporate Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kevin  Wojciechowski", "title": "Head of HCP Marketing & Sales Training", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Darin  Van Arsdale", "title": "Director of Sales Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "maxAge": 86400, "priceHint": 4, "open": 0.27, "dayLow": 0.27, "dayHigh": 0.27, "regularMarketOpen": 0.27, "regularMarketDayLow": 0.27, "regularMarketDayHigh": 0.27, "beta": 1.713, "volume": 2500, "regularMarketVolume": 2500, "averageVolume": 28278, "averageVolume10days": 900, "averageDailyVolume10Day": 900, "bid": 0.15, "ask": 0.3, "marketCap": 417226592, "fiftyTwoWeekLow": 0.0085, "fiftyTwoWeekHigh": 0.5, "priceToSalesTrailing12Months": 201.6087, "fiftyDayAverage": 0.247186, "twoHundredDayAverage": 0.157418, "trailingAnnualDividendYield": "NaN", "currency": "USD", "enterpriseValue": 174657168, "floatShares": 1588607312, "sharesOutstanding": 1817459968, "heldPercentInsiders": 0.14069, "heldPercentInstitutions": 0.13317001, "impliedSharesOutstanding": 2980189952, "bookValue": 0.06, "priceToBook": 2.3333335, "lastFiscalYearEnd": 1719705600, "nextFiscalYearEnd": 1751241600, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -13869709, "trailingEps": -0.01, "enterpriseToRevenue": 84.396, "enterpriseToEbitda": -12.548, "52WeekChange": -0.5333333, "SandP52WeekChange": 0.3464489, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "BXPHF", "underlyingSymbol": "BXPHF", "shortName": "Botanix Pharmaceuticals Ltd.", "longName": "Botanix Pharmaceuticals Limited", "firstTradeDateEpochUtc": 1568035800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "36ad7d44-611b-39f5-bbca-ac91d7b687b5", "messageBoardId": "finmb_324672225", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.14, "recommendationKey": "none", "totalCash": 79308128, "totalCashPerShare": 0.044, "ebitda": -13919372, "quickRatio": 21.469, "currentRatio": 22.213, "totalRevenue": 2069487, "revenuePerShare": 0.001, "returnOnAssets": -0.12738, "returnOnEquity": -0.21065001, "freeCashflow": -20303280, "operatingCashflow": -8127281, "revenueGrowth": 27.532, "grossMargins": -0.76478, "operatingMargins": -5.00466, "financialCurrency": "AUD", "trailingPegRatio": null, "__fetch_time": "2024-10-31"}]